Table 3.
Changes of Lipid Parameters from Baseline to Week 8 of Treatment
| NEBI/RSV vs RSV | NEBI/RSV vs NEBI | ||||
|---|---|---|---|---|---|
| NEBI/RSV (N=92) |
RSV (N=91) |
NEBI (N=93) |
LSmean Difference (95% CI) | LSmean Difference (95% CI) | |
| Total cholesterol | |||||
| Baseline, mg/dl (SD) | 221.21 (28.90) | 217.02 (31.14) | 220.29 (34.88) | ||
| Week 8, mg/dl (SD) | 146.76 (27.48) | 143.00 (28.43) | 218.77 (39.44) | ||
| % change | −33.39 (11.15) | −33.73 (11.27) | −0.37 (12.34) | ||
| LSmean of % changea, mg/dl (SE) | −33.23 (1.15) | −33.89 (1.15) | 0.67 (−2.55, 3.88) | ||
| LSmean of % changeb, mg/dl (SE) | −33.36 (1.21) | −0.40 (1.20) | −32.96 (−36.33, −29.59) | ||
| HDL cholesterol | |||||
| Baseline, mg/dl (SD) | 51.16 (11.73) | 48.15 (12.41) | 47.57 (12.76) | ||
| Week 8, mg/dl (SD) | 53.53 (13.47) | 54.23 (14.01) | 45.40 (11.05) | ||
| % change | 5.75 (18.02) | 13.84 (18.62) | −3.08 (14.56) | ||
| LSmean of % changea, mg/dl (SE) | 6.36 (1.85) | 13.23 (1.86) | −6.88 (−12.08, −1.67) | ||
| LSmean of % changeb, mg/dl (SE) | 6.53 (1.63) | −3.85 (1.62) | 10.38 (5.82, 14.94) | ||
| Triglyceride | |||||
| Baseline, mg/dl (SD) | 167.12 (71.73) | 177.45 (74.40) | 176.37 (76.50) | ||
| Week 8, mg/dl (SD) | 148.00 (84.22) | 129.92 (48.11) | 195.77 (108.26) | ||
| % change | −3.66 (49.56) | −18.01 (42.69) | 16.62 (52.70) | ||
| LSmean of % changea, mg/dl (SE) | −5.05 (4.38) | −16.61 (4.40) | 11.56 (−0.71, 23.83) | ||
| LSmean of % changeb, mg/dl (SE) | −4.64 (5.10) | 17.59 (5.07) | −22.23 (−36.43, −8.03) | ||
| ApoA1 | |||||
| Baseline | 141.43 (22.14) | 136.80 (21.00) | 136.11 (23.38) | ||
| Week 8 | 146.03 (25.61) | 147.07 (27.55) | 132.27 (22.61) | ||
| % change | 3.61 (12.25) | 7.69 (13.08) | −2.17 (11.28) | ||
| LSmean of % change,1 mg/dl (SE) | 3.79 (1.32) | 7.50 (1.32) | −3.71 (−7.40, −0.02) | ||
| LSmean of % change,2 mg/dl (SE) | 3.97 (1.19) | −2.53 (1.19) | 6.50 (3.17, 9.82) | ||
| ApoB | |||||
| Baseline | 128.61 (20.54) | 127.56 (21.35) | 130.46 (22.85) | ||
| Week 8 | 77.98 (19.03) | 74.16 (19.96) | 131.26 (29.50) | ||
| % change | −38.70 (15.26) | −41.37 (14.59) | 1.25 (18.39) | ||
| LSmean of % changea, mg/dl (SE) | −38.61 (1.51) | −41.46 (1.52) | 2.86 (−1.38, 7.09) | ||
| LSmean of % changeb, mg/dl (SE) | −38.86 (1.72) | 1.41 (1.71) | −40.27 (−45.06, −35.49) | ||
| ApoB/A1 ratio | |||||
| Baseline | 0.93 (0.21) | 0.95 (0.22) | 0.99 (0.26) | ||
| Week 8 | 0.55 (0.17) | 0.53 (0.19) | 1.02 (0.29) | ||
| % change | −0.38 (0.20) | −0.43 (0.19) | 0.03 (0.20) | ||
| LSmean of % changea, mg/dl (SE) | −0.39 (0.02) | −0.42 (0.02) | 0.03 (−0.01, 0.08) | ||
| LSmean of % changeb, mg/dl (SE) | −0.39 (0.02) | 0.04 (0.02) | −0.43 (−0.48, −0.38) | ||
| Non-HDL cholesterol | |||||
| Baseline | 170.04 (27.07) | 168.87 (30.96) | 172.72 (34.06) | ||
| Week 8 | 93.23 (26.02) | 88.77 (28.88) | 173.38 (38.08) | ||
| Change | −76.82 (28.15) | −80.10 (28.33) | 0.66 (24.77) | ||
| LSmean of % changea, mg/dl (SE) | −76.51 (2.48) | −80.41 (2.50) | 3.90 (−3.05, 10.85) | ||
| LSmean of % changeb, mg/dl (SE) | −77.23 (2.59) | 1.07 (2.57) | −78.30 (−85.50, −71.09) |
Notes: LSmeana, least-square mean by analysis of covariance model (NEBI/RSV vs RSV) adjusted for baseline value. LSmeanb, least-square mean by analysis of covariance model (NEBI/RSV vs NEBI) adjusted for baseline value.
Abbreviations: NEB/RSV, nebivolol 5 mg/rosuvastatin 20 mg treatment; RSV, rosuvastatin 20 mg alone treatment; NEB, nebivolol 5 mg alone treatment; SD, standard deviation; LSmean, least-square mean; SE, standard error; HDL, high-density lipoprotein, Apo, apolipoprotein.